Analysts Expect Cellectis S.A. (NASDAQ:CLLS) to Announce -$0.61 EPS
Wall Street analysts expect Cellectis S.A. (NASDAQ:CLLS) to post earnings of ($0.61) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Cellectis’ earnings. The highest EPS estimate is ($0.58) and the lowest is ($0.63). Cellectis posted earnings per share of ($0.40) during the same quarter last year, which would indicate a negative year over year growth rate of 52.5%. The business is expected to issue its next quarterly earnings results on Thursday, September 14th.
On average, analysts expect that Cellectis will report full-year earnings of ($2.50) per share for the current financial year, with EPS estimates ranging from ($2.63) to ($2.35). For the next fiscal year, analysts expect that the business will post earnings of ($3.12) per share, with EPS estimates ranging from ($4.02) to ($2.42). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Cellectis.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research report on Wednesday, July 19th. BidaskClub lowered Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Cellectis in a research report on Saturday, June 3rd. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $47.00 target price on shares of Cellectis in a research report on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Cellectis presently has an average rating of “Buy” and an average target price of $41.80.
Shares of Cellectis (NASDAQ CLLS) traded down 0.21% during mid-day trading on Monday, reaching $23.21. 53,437 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $25.17 and a 200-day moving average price of $23.25. Cellectis has a 12 month low of $16.09 and a 12 month high of $28.77. The stock’s market cap is $820.13 million.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Eqis Capital Management Inc. acquired a new position in Cellectis during the first quarter valued at $202,000. Trexquant Investment LP acquired a new position in Cellectis during the first quarter valued at $214,000. Vident Investment Advisory LLC increased its position in Cellectis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock valued at $1,224,000 after buying an additional 8,496 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in Cellectis during the first quarter valued at $3,832,000. Institutional investors own 16.08% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Analysts Expect Cellectis S.A. (NASDAQ:CLLS) to Announce -$0.61 EPS” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/07/analysts-expect-cellectis-s-a-nasdaqclls-to-announce-0-61-eps.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.